药王争霸:礼来“减肥神药”替尔泊肽收入飙升,默沙东K药遭遇最强挑战者!

摩熵医药大数据
Nov 03

10月30日,$LLY(LLY)礼来披露三季度财报,三季度营收176亿美元,同比增长54%。前三季度总营收459亿美元,同比增长46%。替尔泊肽(Mounjaro和Zepbound)和阿贝西利(Verzenio)堪称礼来制药业务营收增长的两大核心驱动力。在2025年前三季度,替尔泊肽实现创收248.37亿美元,同比增长达125%;阿贝西利创收41.18亿美元,同比增长10%。尤为值得关注的是,在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10